On November 22, 2021, Readline announced that it had completed the A+ round and A++ round of equity financing of more than 200 million yuan. The financing fund is mainly used for continuous investment in R&D and talent introduction, so as to continue to enhance the company's leading-edge in the field of synthetic biology and "life molecules".

Readline is an innovative high-tech enterprise with synthetic biotechnology as the core. Readline takes the lead in applying synthetic biotechnology to the all green commercial production of "life molecules", promoting carbon neutralization and carbon emission reduction in the field of characteristic functional raw materials. Its product applications cover the fields of biomedicine, nutrition and health, medical beauty and daily chemicals, animal health care, green agriculture, and biomaterials.

"Life molecules" refer to functional molecules that contain one or more of the basic unit molecules such as amino acids, sugars, and nucleotides and show excellent safety, effectiveness and accessibility.

Since the establishment of the company four years ago, the operating results and scale of the company have continued to expand rapidly. The R&D area has increased by more than 50 times, the R&D personnel has always exceeded 60%, and the core technology and management talents account for more than 25%.